During the last year, marked by a pandemic, Sangair has worked hard to create a proof of concept for its disruptive technology and treatment method of Sepsis, SangAsept.
Amongst other, two partnerships have been created with 2 different research groups at Karolinska Institute, ICU and infection experts respectively, both complementing team Sangair with medical and practical expertise in their specific area.
The results so far, both indicating effect on killing E.Coli in blood and the safety results done on animals indicate that no blood cells was damaged during the treatment.
The intellectual property family has expanded with an approved patent application in Japan, pertaining to ozonation of blood, and more countries are in pipeline the upcoming years.
The company now aims to increase its development pace by increasing the resources associated within and around the company.
We will keep you posted on our development.